Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant

Robert G. Pergolizzi, Rachel Dragos, Alexander E. Ropper, André Menez, Ronald Crystal

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Venomous snakebites result in almost 125,000 deaths per year worldwide. We present a new paradigm for the development of vaccines to protect against snakebite, using knowledge of the structure and action of specific toxins combined with a gene-based strategy to deliver a toxin gene modified to render it non-toxic while maintaining its three-dimensional structure and hence its ability to function as an immunogen. As a model for this approach, we developed a genetic vaccine to protect against α-cobratoxin (CTX), a potent, post-synaptic neurotoxin that is the major toxic component of the venom of Naja kaouthia, the monocellate cobra. To develop the vaccine, substitutions in the CTX cDNA were introduced at two residues critical for binding to the nicotinic acetylcholine receptor (Asp27 to Arg, Arg33 to Gly). The mutated CTX expression cassette was delivered in the context of a replication deficient adenovirus vector (AdmCTX). To assess whether expression of the mutated CTX in vivo leads to the development of protective immunity, BALB/c mice were challenged by IV administration of 2 μg of α-cobratoxin protein 21 or 63 days after administration of AdmCTX or AdNull (as a control; both, 109 particle units). Animals receiving AdmCTX but no α-cobratoxin challenge suffered no ill effects, but ≥80% of naive animals or those receiving the AdNull control vector died within 10 min from the α-cobratoxin challenge. In contrast, 100% of animals receiving a single dose of AdmCTX 21 or 63 days prior to α-cobratoxin challenge survived. The data demonstrates that an adenovirus-based vaccine can be developed to protect against lethal challenge with a potent snake venom. The effectiveness of this approach might serve as a basis to consider the development of a global public health program to protect those at risk for death by snakebite.

Original languageEnglish
Pages (from-to)292-298
Number of pages7
JournalHuman Gene Therapy
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Mar 2005
Externally publishedYes

Fingerprint

Snake Bites
Immunity
Vaccines
Adenovirus Vaccines
Elapidae
Snake Venoms
Poisons
Neurotoxins
Nicotinic Receptors
Adenoviridae
Genes
Complementary DNA
Public Health
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant. / Pergolizzi, Robert G.; Dragos, Rachel; Ropper, Alexander E.; Menez, André; Crystal, Ronald.

In: Human Gene Therapy, Vol. 16, No. 3, 01.03.2005, p. 292-298.

Research output: Contribution to journalArticle

Pergolizzi, Robert G. ; Dragos, Rachel ; Ropper, Alexander E. ; Menez, André ; Crystal, Ronald. / Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant. In: Human Gene Therapy. 2005 ; Vol. 16, No. 3. pp. 292-298.
@article{fe0c20e40bb44392a67891508587365a,
title = "Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant",
abstract = "Venomous snakebites result in almost 125,000 deaths per year worldwide. We present a new paradigm for the development of vaccines to protect against snakebite, using knowledge of the structure and action of specific toxins combined with a gene-based strategy to deliver a toxin gene modified to render it non-toxic while maintaining its three-dimensional structure and hence its ability to function as an immunogen. As a model for this approach, we developed a genetic vaccine to protect against α-cobratoxin (CTX), a potent, post-synaptic neurotoxin that is the major toxic component of the venom of Naja kaouthia, the monocellate cobra. To develop the vaccine, substitutions in the CTX cDNA were introduced at two residues critical for binding to the nicotinic acetylcholine receptor (Asp27 to Arg, Arg33 to Gly). The mutated CTX expression cassette was delivered in the context of a replication deficient adenovirus vector (AdmCTX). To assess whether expression of the mutated CTX in vivo leads to the development of protective immunity, BALB/c mice were challenged by IV administration of 2 μg of α-cobratoxin protein 21 or 63 days after administration of AdmCTX or AdNull (as a control; both, 109 particle units). Animals receiving AdmCTX but no α-cobratoxin challenge suffered no ill effects, but ≥80{\%} of naive animals or those receiving the AdNull control vector died within 10 min from the α-cobratoxin challenge. In contrast, 100{\%} of animals receiving a single dose of AdmCTX 21 or 63 days prior to α-cobratoxin challenge survived. The data demonstrates that an adenovirus-based vaccine can be developed to protect against lethal challenge with a potent snake venom. The effectiveness of this approach might serve as a basis to consider the development of a global public health program to protect those at risk for death by snakebite.",
author = "Pergolizzi, {Robert G.} and Rachel Dragos and Ropper, {Alexander E.} and Andr{\'e} Menez and Ronald Crystal",
year = "2005",
month = "3",
day = "1",
doi = "10.1089/hum.2005.16.292",
language = "English",
volume = "16",
pages = "292--298",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant

AU - Pergolizzi, Robert G.

AU - Dragos, Rachel

AU - Ropper, Alexander E.

AU - Menez, André

AU - Crystal, Ronald

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Venomous snakebites result in almost 125,000 deaths per year worldwide. We present a new paradigm for the development of vaccines to protect against snakebite, using knowledge of the structure and action of specific toxins combined with a gene-based strategy to deliver a toxin gene modified to render it non-toxic while maintaining its three-dimensional structure and hence its ability to function as an immunogen. As a model for this approach, we developed a genetic vaccine to protect against α-cobratoxin (CTX), a potent, post-synaptic neurotoxin that is the major toxic component of the venom of Naja kaouthia, the monocellate cobra. To develop the vaccine, substitutions in the CTX cDNA were introduced at two residues critical for binding to the nicotinic acetylcholine receptor (Asp27 to Arg, Arg33 to Gly). The mutated CTX expression cassette was delivered in the context of a replication deficient adenovirus vector (AdmCTX). To assess whether expression of the mutated CTX in vivo leads to the development of protective immunity, BALB/c mice were challenged by IV administration of 2 μg of α-cobratoxin protein 21 or 63 days after administration of AdmCTX or AdNull (as a control; both, 109 particle units). Animals receiving AdmCTX but no α-cobratoxin challenge suffered no ill effects, but ≥80% of naive animals or those receiving the AdNull control vector died within 10 min from the α-cobratoxin challenge. In contrast, 100% of animals receiving a single dose of AdmCTX 21 or 63 days prior to α-cobratoxin challenge survived. The data demonstrates that an adenovirus-based vaccine can be developed to protect against lethal challenge with a potent snake venom. The effectiveness of this approach might serve as a basis to consider the development of a global public health program to protect those at risk for death by snakebite.

AB - Venomous snakebites result in almost 125,000 deaths per year worldwide. We present a new paradigm for the development of vaccines to protect against snakebite, using knowledge of the structure and action of specific toxins combined with a gene-based strategy to deliver a toxin gene modified to render it non-toxic while maintaining its three-dimensional structure and hence its ability to function as an immunogen. As a model for this approach, we developed a genetic vaccine to protect against α-cobratoxin (CTX), a potent, post-synaptic neurotoxin that is the major toxic component of the venom of Naja kaouthia, the monocellate cobra. To develop the vaccine, substitutions in the CTX cDNA were introduced at two residues critical for binding to the nicotinic acetylcholine receptor (Asp27 to Arg, Arg33 to Gly). The mutated CTX expression cassette was delivered in the context of a replication deficient adenovirus vector (AdmCTX). To assess whether expression of the mutated CTX in vivo leads to the development of protective immunity, BALB/c mice were challenged by IV administration of 2 μg of α-cobratoxin protein 21 or 63 days after administration of AdmCTX or AdNull (as a control; both, 109 particle units). Animals receiving AdmCTX but no α-cobratoxin challenge suffered no ill effects, but ≥80% of naive animals or those receiving the AdNull control vector died within 10 min from the α-cobratoxin challenge. In contrast, 100% of animals receiving a single dose of AdmCTX 21 or 63 days prior to α-cobratoxin challenge survived. The data demonstrates that an adenovirus-based vaccine can be developed to protect against lethal challenge with a potent snake venom. The effectiveness of this approach might serve as a basis to consider the development of a global public health program to protect those at risk for death by snakebite.

UR - http://www.scopus.com/inward/record.url?scp=16344371197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344371197&partnerID=8YFLogxK

U2 - 10.1089/hum.2005.16.292

DO - 10.1089/hum.2005.16.292

M3 - Article

C2 - 15812224

AN - SCOPUS:16344371197

VL - 16

SP - 292

EP - 298

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -